Prior to DxS, Jeff held positions as Executive VP and Executive Committee member of Shire Pharmaceuticals, where he played a key role in strategy and integration. Before this he was a Partner in Ernst and Young’s life science division. Jeff has a BSc in Physics from the University of Edinburgh and an MSc in Marketing from the University of Strathclyde.
Dr. Stephen Little, CEO of DxS, said: “Jeff’s appointment significantly strengthens the DxS management team and with his strong background in operations and strategy, his expertise will be critical as the company continues its planned expansion.”
The appointment is one of a number planned for 2009, continuing DxS’ expansion which has seen the company’s workforce more than double in size in the last twelve months with new manufacturing space taken at their Manchester site and a global distribution deal agreed with Roche Molecular Diagnostics for their TheraScreen® diagnostic kits. DxS is a personalised medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies to support the development and sales of targeted cancer therapies by providing biomarkers and companion diagnostics.
DxS has a continually expanding portfolio of cancer mutation products. The TheraScreen® range of CE-marked clinical diagnostic kits can identify genetic tumour mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS produce two clinical diagnostic kits, K-RAS and EGFR-29.
The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS has an exclusive global distribution agreement with Roche Diagnostics for the distribution of the TheraScreen: K-RAS and TheraScreen: EGFR29 Mutation kits.
DxS’ pioneering real-time PCR technology Scorpions® is highly regarded for its proven speed and sensitivity, and is combined with ARMS (allele specific PCR) to develop each unique DxS product. This class-leading technology is also available for licence to diagnostic companies, for research, or for other varied applications.
DxS is a private, venture capital-backed company operating from the heart of Manchester’s Technology Quarter in the UK.
For further information please visit www.dxsdiagnostics.com
